GROUP I: Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 28 (may occur as early as day 21) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.